Multi-center randomized controlled trial of gemcitabine in combination with gimeracil/oteracil/tegafur compared with gemcitabine alone in patients with advanced nonresectable pancreatic cancer.

Trial Profile

Multi-center randomized controlled trial of gemcitabine in combination with gimeracil/oteracil/tegafur compared with gemcitabine alone in patients with advanced nonresectable pancreatic cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms GEMSAP
  • Most Recent Events

    • 18 Jan 2014 Pooled results for prognostic factors from GEST, GEMSAP, and JACCRO PC-01 presented at the 2014 Gastrointestinal Cancers Symposium.
    • 07 Jun 2011 Final overall survival results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2010 Results from first analysis have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top